NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/24/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization16,614 mln
Float65.59 mln
Earnings Date11/11/2026
EPS
13.07
Robust
P / E
19.28
Moderately valued
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
3.38
Highly suspicious
1-Year Forecast
313
Attractive
Relative Strength
34
/ 100
Underperforming
Business Description
Founded in Denmark in 2006, Ascendis Pharma is a drug development company built around its proprietary TransCon technology, which is designed to improve how medicines work in the body. The company currently sells two approved treatments ? one for children with growth hormone deficiency and another for adults with a rare condition affecting calcium regulation. Beyond these products, Ascendis is advancing additional treatments for rare hormonal disorders and exploring new therapies in cancer care.
